Published in Drug Law Weekly, August 16th, 2005
Prostate cancer is the most-commonly diagnosed nonskin cancer in the United States and the third most common cancer worldwide.
In the D9902A study, the 3-year final survival analysis in the intent-to-treat population of the double-blind, placebo-controlled study of Provenge in 98 men with asymptomatic, metastatic, androgen-independent...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Law Weekly